Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism by Lutz, Thomas A & Osto, Elena
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism
Lutz, Thomas A; Osto, Elena
Abstract: PURPOSE OF REVIEW: Glucagon-like peptide-1 (GLP-1) is the best known incretin hormone
able to potentiate glucose-induced insulin secretion. Moreover, GLP-1 is currently under intensive inves-
tigation as a potential crucial mediator of beneficial metabolic effects after bariatric surgery, because of
its eating inhibitory, antiobesity, and antidiabetes effects. This review briefly summarizes recent findings
on the specific effects of GLP-1 on lipoprotein metabolism. The related hormone GLP-2 is derived from
the same precursor gene; its effects on lipoprotein metabolism will also be discussed briefly. RECENT
FINDINGS: Pharmacological activation of the GLP-1 system has beneficial effects on obesity-induced
alterations of lipoprotein metabolism. These benefits can be observed with direct GLP-1 receptor ago-
nists like liraglutide or exendin-4, but also with inhibitors of dipeptidyl peptidase IV (DPP-IV), which
reduce the breakdown of endogenous GLP-1. The role of GLP-2-related pathways on lipid levels and
metabolism are less clear, but some effects (e.g. increased intestinal chylomicron output) are opposite
to GLP-1. SUMMARY: Activation of the GLP-1-dependent pathways may perhaps translate into a
lower cardiovascular risk. Understanding how GLP-1 and GLP-2 regulate and interact in the control of
lipoprotein metabolism will set the stage for the development of new strategies to treat dyslipidaemia in
obesity, diabetes, and other cardiometabolic diseases.
DOI: https://doi.org/10.1097/MOL.0000000000000293
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-133609
Published Version
Originally published at:
Lutz, Thomas A; Osto, Elena (2016). Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism.
Current Opinion in Lipidology, 27(3):257-263.
DOI: https://doi.org/10.1097/MOL.0000000000000293
 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
 CURRENTOPINION Glucagon-like peptide-1, glucagon-like peptide-2,
and lipid metabolism
Thomas A. Lutza,b and Elena Ostob,c,d
Purpose of review
Glucagon-like peptide-1 (GLP-1) is the best known incretin hormone able to potentiate glucose-induced
insulin secretion. Moreover, GLP-1 is currently under intensive investigation as a potential crucial mediator
of beneficial metabolic effects after bariatric surgery, because of its eating inhibitory, antiobesity, and
antidiabetes effects. This review briefly summarizes recent findings on the specific effects of GLP-1 on
lipoprotein metabolism. The related hormone GLP-2 is derived from the same precursor gene; its effects on
lipoprotein metabolism will also be discussed briefly.
Recent findings
Pharmacological activation of the GLP-1 system has beneficial effects on obesity-induced alterations of
lipoprotein metabolism. These benefits can be observed with direct GLP-1 receptor agonists like liraglutide
or exendin-4, but also with inhibitors of dipeptidyl peptidase IV (DPP-IV), which reduce the breakdown of
endogenous GLP-1. The role of GLP-2-related pathways on lipid levels and metabolism are less clear, but
some effects (e.g. increased intestinal chylomicron output) are opposite to GLP-1.
Summary
Activation of the GLP-1-dependent pathways may perhaps translate into a lower cardiovascular risk.
Understanding how GLP-1 and GLP-2 regulate and interact in the control of lipoprotein metabolism will set
the stage for the development of new strategies to treat dyslipidaemia in obesity, diabetes, and other
cardiometabolic diseases.
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INTRODUCTION
Glucagon-like peptide 1 (GLP-1) is the best studied
gut-derived incretin hormone. The incretin effect
describes the phenomenon that glucose triggers a
stronger increase in insulin secretion when given
orally as compared with an intravenous infusion;
the higher insulin secretion is observed when oral or
intravenous glucose are compared for their insulin
releasing effects under conditions when they lead to
the same changes in blood glucose levels [1–3].
Because of their capacity to increase insulin
secretion and to inhibit pancreatic glucagon
secretion, GLP-1 receptor (GLP-1R) agonists and
inhibitors of dipeptidyl peptidase-IV (DPP-IV),
which reduce the breakdown of endogenous
GLP-1, are cornerstones of today’s antidiabetic
therapy. A second boost to the study of GLP-1-
mediated effects followed the observation that
some effects of bariatric surgery, in particular of
the Roux-en-Y gastric bypass (RYGB) and the verti-
cal sleeve gastrectomy (VSG) may depend on the
exaggerated secretion of gut hormones, including
GLP-1, after surgery. The contribution of GLP-1 to
bariatric surgery benefits is still a matter of debate,
but it is clear that GLP-1 produces a large number of
effects (e.g. reduction in eating; increase in insulin
secretion) that are also induced by RYGB and VSG
[4–6]. The potent reduction in eating by GLP-1 led
to the recent approval of the GLP-1R agonist lira-
glutide for the treatment of obesity in the USA.
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(http://www.fda.gov/NewsEvents/Newsroom/Press
Announcements/ucm427913.htm).
The first randomized trial indicated that liraglu-
tide treatment over 1 year as an adjunct to diet and
exercise was associated with reduced body weight
and improved metabolic control in a population of
nondiabetic patients with dyslipidaemia or hyper-
tension [7
&&
]. In particular, the fasting lipid profile
was markedly improved in the liraglutide-treated
patients, including significant decreases in total
cholesterol and plasma triglycerides (TAG), and
increases in HDL cholesterol (HDL-C).
Hence, beyond the well studied incretin effects,
this class of hormones exerts a number of pleio-
tropic actions that may be beneficial in cardiome-
tabolic disease. The main topic of this brief review is
to summarize effects of incretins, in particular
GLP-1, but also of GLP-2, on lipid metabolism.
We will concentrate on the recently published liter-
ature on extrapancreatic effects of GLP-1 and GLP-2.
Glucose-dependent insulinotropic polypeptide
(GIP; also called gastric inhibitory polypeptide) is
another hormone with well known incretin action
but GIP’s role in the control of lipid metabolism is
less clear than for GLP-1. GIP is known to improve
LDL clearance, but at the same time to favour an
unhealthy type of fat distribution with a decrease in
subcutaneous and an increase in intra-abdominal
fat [8
&
]. Hence, more research needs to be done to
better understand the role of GIP in lipid meta-
bolism.
Dyslipidaemia, which frequently accompanies
diseases like the metabolic syndrome and type 2
diabetes mellitus contributes to the elevated risk
of cardiovascular disease under these conditions.
The proatherosclerotic lipid abnormalities include
elevated levels of plasma TAG and TAG-rich VLDL
and chylomicrons. Further, dyslipidaemia includes
high levels of LDL cholesterol (LDL-C) together with
low levels of HDL-C. Quantitative but also qualita-
tive changes in lipoprotein structure and function,
for example, altered glycation and oxidation of lip-
oprotein particles and altered function of HDL-C,
are present [9
&
,10,11
&&
].
The alterations in lipoprotein metabolism
mutually influence each other; elevated TAG-rich
lipoproteins contribute to lower HDL levels and to
elevated levels of LDL. Further, insulin resistance
and type 2 diabetes mellitus are associated with an
increased production of TAG-rich lipoproteins in
the intestine [characterized by their apolipoprotein
(Apo)B-48 content] and in the liver (characterized
byApoB-100) (for review: [12,13]). In particular, the
intestinal production of lipoproteins is modulated
byGLP-1 but alsoGLP-2. Although it is derived from
the same preproglucagon gene [14] and is released
from the same intestinal L cells in the same molar
ratio as GLP-1, GLP-2 does not exert incretin
actions.
Production site of glucagon-like peptide-1
and glucagon-like peptide-2
GLP-1 and GLP-2 are secreted from enteroendocrine
L cells [1,15]. Two important issues are unclear. First,
it is unknown which part of the gastrointestinal
tract contributes most to circulating GLP-1 because
the density of theGLP-1 andGLP-2 producing L cells
is higher in distal parts of the small intestine and in
the colon, but the highest total number of L cells at
least in rats is in the jejunum [16]. Second, L cells
express various receptors and transporters that trig-
ger L-cell secretion in response to a large variety of
stimuli, such as glucose, long or short-chain fatty
acids but also bile acids [17]. However, it is a matter
of debate which of these stimuli contributes most to
the postprandial release of GLP-1 and GLP-2; there
are even more uncertainties about their contri-
bution to the elevated basal and postprandial
GLP-1 and GLP-2 levels after RYGB or VSG because
of the altered transit of the food and anatomical
rearrangement of the gut after these procedures
[16,18–22,23
&&
].
GLP-1 is also produced in a subset of neurons in
the nucleus of the solitary tract (NTS). GLP-1
analogues have recently been shown to control
intestinal lipoprotein secretion when administered
directly into the central nervous system [24
&&
],
whether this effect mimics the action of GLP-1
released from NTS neurons and whether this has a
specific role in the control of lipidmetabolism needs
further clarification.
Sites of glucagon-like peptide-1 action to
increase insulin secretion and to reduce
eating
GLP-1-dependent actions are mediated by different
receptor populations. GLP-1’s incretin effect is
mediated by direct action on pancreatic b-cells
KEY POINTS
 GLP-1 improves dyslipidaemia in obesity.
 GLP-1 directly affects intestinal lipoprotein metabolism.
 GLP-1’s effect on liver lipoprotein metabolism
is indirect.
 GLP-2 has opposite effects compared with GLP-1.
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[25], but part of the effect may also depend on
activation of vagal afferent neurons [26]. GLP-1’s
eating inhibitory effect also depends on a paracrine
action via intestinal vagal afferents, which trans-
mit the signal to the NTS [27]. Whether a direct
action of endogenous GLP-1 on the brain also plays
a role for the eating inhibitory effect under phys-
iological conditions is a matter of debate; this may
be different from exogenously applied GLP-1 ago-
nists like liraglutide because their direct access to
the brain is facilitated by the compound’s chemical
structure [28]. Details for the site of GLP-1’s effects
on lipid metabolism will be discussed in the sub-
sequent sections; depending on the target organ,
part of the effects seems to be direct (e.g. on intes-
tinal epithelial cells), and part seems indirect
(e.g. central nervous system-mediated effects on
the liver).
Glucagon-like peptide-1 and lipid metabolism
GLP-1 agonists like exendin-4 or liraglutide and
DPP-IV inhibitors have been shown to improve
basal and postprandial lipaemia in a number of
animal models and also in humans [7
&&
,29
&
,30].
Improved lipaemia typically includes reduced levels
of LDL-C, total cholesterol, and TAG. A network
meta-analysis has recently reviewed the most
important clinical studies, which prove the
beneficial effects of such treatment on dyslipidae-
mia [29
&
]. GLP-1 agonists and DPP-IV inhibitors do
not consistently increase HDL-C levels [29
&
] which
at first sight may seem counterintuitive. It is import-
ant to highlight that the vascular-protective proper-
ties of HDL may be more relevant than the HDL-C
concentration alone to inhibit atherosclerosis [31
&&
].
Along this line, in a recent study early after RYGB,
elevated plasmatic GLP-1 levels were associated with
an improved capacity of HDL to stimulate excessive
cholesterol efflux from macrophages; further, at the
endothelial level, HDL stimulation induced nitric
oxide production, and exerted anti-inflammatory
and antiapoptotic actions not only in a rat RYGB
model but also in patients. Interestingly, liraglutide
treatment in diet-induced obese rats rapidly
improved the functions of HDL and mimicked the
beneficial effect of RYGB surgery. This functional
improvement occurred despite unchanged HDL-C
concentration [23
&&
].
Liraglutide also seems to affect the distributionof
cholesterol within specific lipoprotein subclasses. In
patients, liraglutide caused a shift away from small,
dense LDL particles, and it decreased the apolipopro-
tein B concentration [30]. In our own study, we
showed that the HDL-C particle size was shifted
toward smaller size HDL particles by RYGB surgery
in diet-induced obese rats, and this effect was mim-
icked by liraglutide [23
&&
]. Recent evidence suggests
that small dense HDL particles may be of clinical
relevance as a major mediator of the cardiovascular
protective properties of HDL [32,33
&
]. Finally, indi-
rect evidence also supports a role of GLP-1 in
improved lipaemia after RYGB, because the most
pertinent changes like decreased postprandial
LDL-C and TAG, and increased HDL-C after RYGB
werebest predictedby the associatedGLP-1peak [34].
Regarding atherosclerosis, which is the vascular
consequence of chronic pathologic alterations in
lipid levels, DPP-IV inhibition has been shown to
reduce plaque inflammation and increase plaque
collagen content in respective mouse models
[35,36]. GLP-1 and its split products were reported
to reduce plaque vulnerability in a mouse model of
vascular disease without affecting atherosclerotic
lesion size [37]. Further, liraglutide treatment
seemed to prevent and stabilize early onset athero-
sclerotic vascular disease partially through GLP-1R-
dependent mechanisms but had no significant
effect on the progression of late onset, high-burden
atherosclerotic disease [38]. Recently, treatment
with engineered fusion proteins constituted by
GLP-1 fused to the globular domain of adiponectin
has been reported to reduce atherosclerosis and
glucose intolerance in ApoE/ mice fed a high-
fat diet [39]. To the best of our knowledge, there
are no published studies assessing specifically
the role of GLP-2 on atherosclerosis processes or
plaque vulnerability.
Role of the intestine in glucagon-like
peptide-1’s effects on blood lipids
Intestinal and hepatic metabolism of lipids and lip-
oproteins are the two major players affecting lipae-
mia. A number of studies suggest that GLP-1 may
influence both organs in a different way: with a
direct local action at the intestinal level and with
an indirect modulation on the liver. GLP-1 agonism
has been shown to reduce the activity of jejunal
microsomal triglyceride transfer protein and of
jejunal TAG availability in hamsters. Further, the
reduction in the concentration of chylomicrons was
due to reduced production rather than increased
clearance of these compounds. Hence, GLP-1 ago-
nists (e.g. exendin-4) and reduced GLP-1 breakdown
(e.g. by sitagliptin) in experimental animals or in
humans lead to a direct reduction in intestinal lipo-
protein synthesis so that less TAG and less ApoB-48
reached the circulation after oral lipid adminis-
tration [40,41
&&
,42]; to our knowledge, it is unclear
how the TAG that are not packaged into chylomi-
crons will eventually be metabolized. Exendin-4 or
Glucagon-like peptide-1, peptide-2, and lipid metabolism Lutz and Osto
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sitagliptin also reduced postprandial free fatty acid
levels in patients [41
&&
,43].
Direct action in the intestine
It is generally believed that the above-mentioned
effects are direct effects at the intestinal level, for
example on intestinal ApoB-48 production. A direct
mode of action is also supported by in-vitro studies
with isolated hamster enterocytes because exendin-
4 inhibited ApoB-48 secretion also under these con-
ditions [11
&&
,42]. The molecular mechanisms of
GLP-1’s influence on chylomicron synthesis, assem-
bly, and secretion in enterocytes are still unknown.
Indirect action via the brain
Indirect actions may to some extent contribute to
GLP-1’s effects on intestinal lipid and lipoprotein
handling. These may, for example include a
reduction in the rate of gastric emptying and gastric
lipase activity, which lead to a lower availability and
lower rate of processing of dietary fat. Indirect
effects mediated by GLP-1 action in the central
nervous system may also play some role, but more
detailed studies will be necessary in the future
[11
&&
,24
&&
] (see also below).
Role of the liver and brown adipose tissue in
glucagon-like peptide-1’s effects on blood
lipids
Dyslipidaemia in obesity and diabetes are associ-
ated with alterations in hepatic lipid metabolism.
At least some of these alterations can be corrected
by GLP-1. GLP-1 agonists, for example reduce hep-
atic VLDL overproduction and de novo lipogenesis
in hamsters. These effects were associated with
decreased hepatic lipid accumulation, and a
decrease in circulating VLDL-bound TAG and
plasmatic ApoB-100 [44
&
].
Indirect action via insulin release and the
brain
In contrast to GLP-1’s effect in the intestine, most of
GLP-1’s hepatic effects seem to be mediated
indirectly. The antilipolytic effect and the effect
to lower free fatty acids, TAG-rich VLDL, and chy-
lomicrons seem to be driven by insulin; hence, they
depend on GLP-1’s incretin effect [11
&&
,40]. Part of
these effects may also be mediated by the central
nervous system because centrally administered
exendin-4 increases peripheral energy utilization
and decreases hepatic lipid synthesis. Because the
effect was blocked by vagotomy, modulation of
parasympathetic nerve activity may mediate part
of the indirect effects of GLP-1 on the liver [44
&
].
Indirect action via the sympathetic nervous
system and brown fat
Finally, increased peripheral energy utilization may
result from an enhanced burning of fat and an
activation of brown adipose tissue function
[44
&
,45
&
]. The latter effect may also be mediated
by the central nervous system because GLP-1
increases thermogenesis via the brain and because
central exendin-4 has been shown to increase brown
adipose tissue function and subsequently to lower
TAG levels [45
&
]. The effects of central exendin-4 to
reduce the TAG content in lipoproteins and to
reduce ApoB-48 seem to be mediated via sympath-
etic nervous system activation [24
&&
] and may there-
fore also be linked to an enhanced burning of fat.
The reduction of ApoB-48 observed after central
administration of exendin-4 indicates that the
reduced chylomicron formation by enterocytes
depends on direct activation of intestinal GLP-1
receptors (as discussed above) and GLP-1-mediated
central nervous system effects via sympathetic acti-
vation [24
&&
]. The effects of central exendin-4 on
peripheral lipidmetabolism seem to be independent
of exendin-4’s effects on food intake or body weight
[46].
Effect of glucagon-like peptide-1 to improve
hepatic steatosis
Exendin-4 or liraglutide has been shown to reduce
the occurrence and degree of hepatic steatosis inde-
pendent of their action on body weight [47]. These
effects were observed in experimental animals but
also in the clinical setting. Liraglutide, for example
improves metabolic dysfunction and insulin resist-
ance, reduces lipotoxicity in the liver, and counter-
acts the pathogenesis of nonalcoholic hepatic
steatosis [48,49
&
].
Indirect action via enhanced insulin release
and sensitivity
Similar to GLP-1’s hepatic action on circulating
lipids, this effect seems to be indirect and related
to increased insulin release and sensitivity [48]. The
beneficial effects on hepatic lipid accumulation and
on metabolic parameters in fatty liver disease seem
to be because of reduced inflammation and endo-
plasmic reticulum stress [50]. The antioxidative and
anti-inflammatory effects were also associated
with an inactivation of the proinflammatory c-Jun
N-terminal kinase pathway [49
&
]. Further, the
antioxidative, cell-protective levels of glutathione
were increased by exendin-4, which suggests that
GLP-1 receptor agonists play a beneficial role against
increased oxidative stress [51].
Lipid metabolism
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Glucagon-like peptide-1 mediated but
glucagon-like peptide-1R-independent
processes
In some, but not all previously discussed studies,
the effects of GLP-1 agonists or inhibitors of GLP-1
breakdown were suggested to be mediated by the
GLP-1R because of their reversal after adminis-
tration of the receptor blocker exendin-9. We
and others, however, reported actions of GLP-1
or of its split products, which appear to be medi-
ated by an additional not yet identified GLP-1
receptor system [37]. In our recent experiments,
we compared effects of RYGB surgery and of direct
GLP-1 receptor activation on the cardiovascular
system and parameters of lipoprotein metabolism
in rats. The beneficial effects of RYGB on the vas-
cular endothelium were mimicked by liraglutide
and blocked by exendin-9, which suggests an
involvement of the known GLP-1R [23
&&
]. In the
same study, however, we also observed that GLP-1
favoured lipid metabolism by a mechanism that
presumably was independent of the known GLP-1R
[23
&&
]. In other words, GLP-1 mimicked RYGB
effects on the circulating lipoprotein concen-
tration and function, but these effects were not
blocked by exendin-9, that is, HDL properties were
not impaired in RYGB rats receiving exendin-9
chronically [23
&&
]. It remains to be clarified which
type of receptor may be responsible for the latter
liraglutide-induced effects.
Glucagon-like peptide-1 versus glucagon-
like peptide-2
In contrast to the effects ofGLP-1,GLP-2 has recently
been demonstrated to enhance intestinal lipoprotein
release. In hamsters, GLP-2 stimulated enterocyte fat
absorption and intestinal chylomicron output
[42,52,53
&&
]. The mechanism of action is not clear
because the GLP-2 receptor is not expressed in enter-
ocytes;whether this indicates that the relevant recep-
tor still needs to be identified, or that the effect is
indirect, needs to be investigated. Blockade of nitric
oxide synthesis reduced the GLP-2-stimulated
secretion of ApoB-48, and nitric oxide donors
increased the release of TAG-rich lipoproteins in vivo
and in vitro; hence, nitric oxide seems to be
required for the mobilization and secretion
of stored TAG after GLP-2 stimulation. Similarly,
GLP-2 stimulation also led to a rapid increase in
ApoB-48 and enhanced the secretion of intestinal
apolipoprotein in humans [54].
Interestingly, GLP-1 reduces and GLP-2
increases intestinal chylomicron release. This sup-
ports the idea that the two hormones are part of the
fine regulation of intestinal chylomicron metab-
olism with opposite counterregulatory effects. A
recent study in hamsters showed that an acute
coinfusion of GLP-1 and GLP-2 resulted in a net
increase in lipid absorption, associated with
increased TAG and ApoB-48. In contrast, an
extended 2-h coinfusion or a blockade of GLP-1
GLP-1
Blood lipids:
reduced LDL
reduced TAG
reduced total cholesterol
Chylomicron production
Lipoprotein synthase
ApoA48 production
VLDL production
Lipogenesis
Lipid accumulation
ApoB100
Insulin
synthesis
Fat oxidation
Thermogenesis
Eating
SNS activation
FIGURE 1. Summary of glucagon-like peptide-1 (GLP-1)-mediated effects on lipid metabolism. GLP-1, which is released from
intestinal L cells acts directly on the intestine, the brown adipose tissue, the brain, and the pancreas. The latter effects
contribute to GLP-1’s effects on hepatic lipid metabolism and eventually on blood lipid levels. For details, please see text. Red:
inhibitory effect; green: stimulatory effect.
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breakdown by DPP-IV inhibition decreased post-
prandial lipaemia. It, therefore, seems that acutely,
the effect of GLP-2 may dominate, but sustained
GLP-1 activity will eventually result in lower lip-
oprotein levels [52].
CONCLUSION
The review briefly summarizes some recent findings
on the effects of GLP-1 and GLP-2 on lipoprotein
metabolism (Fig. 1). Pharmacological activation of
the GLP-1 system has clear beneficial effects on
lipoprotein metabolism. Effects can be observed
with direct GLP-1R agonists like liraglutide or exen-
din-4, but also with DPP-IV inhibitors, which reduce
the breakdown of endogenous GLP-1. It needs to be
shown that the effects of GLP-1 activation will even-
tually translate into a lower cardiovascular risk.
Understanding the control of lipoprotein metab-
olism by GLP-1 may offer new insights into the
development of new strategies to treat dyslipidae-
mia. Overall, the described effectsmay be an import-
ant basis for the further development of drugs to
treat dyslipidaemia in obesity, diabetes, and other
cardiometabolic diseases.
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